Dr. Shreyas Kalantri outlines the phase 3 PROTEUS trial design, showing perioperative apalutamide plus ADT improved pathologic response and metastasis-free survival.
PROTEUS Trial: Perioperative Apalutamide in High-Risk Prostate Cancer
Dr. Shreyas Kalantri explains how PSMA PET imaging revealed the metastasis-free survival benefit in PROTEUS that conventional imaging alone missed.
Dr. Shreyas Kalantri reviews the safety profile of apalutamide plus ADT in PROTEUS, including rash management and comparable grade 3/4 adverse event rates.
Dr. Shreyas Kalantri discusses PROTEUS's practice-changing takeaways for high-risk prostate cancer and the open questions future studies still need to answer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Alcohol-Attributable Cancer Mortality Has Doubled in the US Since 1990
2
Unpacking Iberdomide’s FDA Approval and The Future of CELMoDs
3
FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
4
How Will Ropeginterferon Alfa’s Approval Impact Essential Thrombocythemia?
5